```html

Bilirubin Encephalopathy (Kernicterus) – Complete Medical Guide

Overview

Bilirubin encephalopathy, historically called kernicterus, is a rare but serious form of brain injury that occurs when very high levels of unconjugated (indirect) bilirubin cross the newborn’s blood‑brain barrier and deposit in the basal ganglia, brainstem nuclei, and cerebellum. The condition most commonly affects full‑term and preterm infants during the first week of life, a period when the liver’s ability to process bilirubin is still immature.

Worldwide estimates suggest that severe hyperbilirubinemia occurs in 1–2 per 1,000 live births, but the incidence of kernicterus has declined dramatically in high‑resource settings (< 0.1 per 1,000) thanks to universal newborn screening and phototherapy protocols. In low‑ and middle‑income countries the burden remains higher, with some studies reporting up to 10 cases per 1,000 live births where timely treatment is unavailable.

Because bilirubin can cause permanent neurologic damage, early recognition and rapid treatment are essential.

Symptoms

The clinical picture evolves in three overlapping phases: early (<72 h), intermediate (3–7 days), and chronic (months‑to‑years). Not every infant shows all findings.

Early (Acute) Signs (first 72 h)

• Lethargy or poor feeding: The baby becomes unusually sleepy, difficult to awaken.
• Hypotonia: Decreased muscle tone, “floppy” appearance.
• High‑pitch cry: A shrill, incongruent cry may precede other signs.
• Seizures: May be subtle (eye blinking, lip smacking) or overt tonic‑clonic.

Intermediate (Sub‑Acute) Signs (3–7 days)

• Auditory brain‑stem dysfunction: Poor startle response to sound.
• Movement abnormalities: Choreo‑athetosis (involuntary writhing movements), dystonia, or “spastic‑diplegic” pattern.
• Oculomotor dysfunction: Nystagmus, ophthalmoplegia, or gaze palsy.
• Feeding difficulties continue: Weak suck, frequent vomiting.
• Developmental regression: Loss of previously acquired milestones.

Chronic (Late) Signs (months‑years)

• Permanent motor deficits: Cerebral palsy, especially spastic diplegia.
• Auditory neuropathy: Sensorineural hearing loss requiring amplification or cochlear implants.
• Dental enamel hypoplasia: Yellow‑brown staining of teeth.
• Cognitive impairment: Learning difficulties, reduced IQ.
• Behavioral problems: Hyperactivity, autism‑spectrum features in some cases.

Causes and Risk Factors

Kernicterus is not a disease itself but a complication of **severe unconjugated hyperbilirubinemia**. The underlying mechanisms that raise bilirubin levels include:

Common Causes

• Physiologic newborn jaundice: Normal breakdown of fetal hemoglobin; peaks at 3‑5 days in term infants, 5‑7 days in preterms.
• Hemolytic disease of the newborn (HDN): ABO or Rh incompatibility leading to rapid red‑cell destruction.
• Genetic enzyme deficiencies:
  • Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency.
  • Crigler‑Najjar type I (severe UDP‑glucuronosyltransferase deficiency).
• Breast‑feeding jaundice: Inadequate intake → dehydration, reduced stool output, higher enterohepatic circulation.
• Breast‑feeding jaundice (early): Lack of colostrum intake in the first 24 h.
• Sepsis or necrotizing enterocolitis: Inflammation increases bilirubin production and impairs conjugation.
• Prematurity: Immature glucuronidation pathways; lower albumin binding capacity.
• Medications that displace bilirubin from albumin: Sulfonamides, chloramphenicol, some NSAIDs.

Risk Factors for Developing Kernicterus

• Serum total bilirubin > 20 mg/dL (340 µmol/L) in term infants or > 15 mg/dL (255 µmol/L) in preterms.
• Albumin < 2.5 g/dL (low binding capacity).
• Acidosis, hypoxia, or sepsis (increase blood‑brain barrier permeability).
• Concurrent use of drugs that compete for albumin binding.
• Family history of bilirubin‑processing disorders.
• Delayed or inadequate feeding (especially in the first 48 h).

Diagnosis

Because the condition can progress rapidly, diagnosis relies on a combination of clinical suspicion, laboratory data, and imaging.

Laboratory Tests

• Serum total bilirubin (TSB): Measured by spectrophotometry; values plotted on age‑specific nomograms (e.g., Bhutani).
• Direct (conjugated) vs. indirect (unconjugated) fractions: Kernicterus is linked to the indirect fraction.
• Serum albumin level: Low albumin increases free bilirubin.
• Blood gases and pH: Acidosis intensifies bilirubin neurotoxicity.
• Hemolysis work‑up: Coombs test, G6PD screen, blood type.

Neuro‑imaging

• Brain MRI: T1‑weighted hyperintensity in the globus pallidus, subthalamic nuclei, hippocampus, and cerebellar dentate nuclei is classic for kernicterus.
• Diffusion‑weighted imaging (DWI): May show early cytotoxic edema before T1 changes.

Auditory Testing

• Brain‑stem evoked response audiometry (BERA): Detects auditory nerve dysfunction often before clinical hearing loss appears.

Clinical Scoring Systems

• The American Academy of Pediatrics (AAP) Hyperbilirubinemia Risk Chart helps decide when to intervene.
• In suspected kernicterus, the Kernicterus Severity Score (KSS) quantifies neurologic involvement (motor, auditory, visual, and cognitive domains).

Treatment Options

Therapy focuses on rapidly lowering free bilirubin, preventing further neurotoxicity, and supporting organ function.

Phototherapy (Primary Therapy)

• Blue‑green light (460‑490 nm) converts bilirubin into water‑soluble isomers (photo‑isomers) that can be excreted without conjugation.
• Standard intensity: ≥30 µW/cm²/nm; exchange‑able double‑surface units for severe cases.
• Duration: Typically 24–72 h, but continued until TSB falls below risk thresholds.

Exchange Transfusion (ET)

• Indicated when TSB exceeds the exchange‑transfusion threshold (e.g., > 25 mg/dL in term infants) or when neuro‑toxic signs appear despite maximal phototherapy.
• Replaces infant’s blood with donor packed red cells, reducing bilirubin by ≈ 50 % per exchange.
• Risks: electrolyte imbalances, thrombocytopenia, infection, and vascular complications.

Adjunctive Measures

• Intravenous immunoglobulin (IVIG): Useful for iso‑immune hemolysis (e.g., Rh incompatibility) to reduce hemolysis and bilirubin production.
• Albumin infusion: May raise binding capacity; evidence is limited and usually reserved for severe cases with hypoalbuminemia.
• Hydration and feeding optimization: Frequent breastfeeding or expressed breast milk to promote stool output and bilirubin elimination.

Long‑Term Management

• Hearing rehabilitation: Early BERA screening, hearing aids, or cochlear implants.
• Physical & occupational therapy: To address motor deficits and prevent contractures.
• Neurodevelopmental follow‑up: Regular assessments through early childhood.

Living with Bilirubin Encephalopathy (Kernicterus)

Families often need a multidisciplinary approach. Below are practical tips for day‑to‑day care.

Medical Follow‑Up

• Schedule neurologic examinations at 1, 3, 6, 12, and 24 months.
• Hearing tests at birth, 3 months, and annually until age 5.
• Vision screening: Look for gaze palsy or nystagmus; refer to pediatric ophthalmology.

Home Care

• Positioning: Alternate limbs to avoid contractures; use supportive cushions.
• Feeding: Encourage frequent, small feeds; consider lactation consulting if breastfeeding.
• Temperature regulation: Keep the infant cool; excessive heat can increase bilirubin production.
• Stimulating environment: Gentle auditory stimulation (soft music) can aid language development, but avoid loud noises that may over‑stimulate the auditory pathway.
• Medication safety: Avoid drugs that displace bilirubin (e.g., sulfonamides) unless prescribed by a specialist.

Educational Support

• Enroll early‑intervention services for speech, occupational, and physical therapy.
• Work with school systems to arrange individualized education plans (IEPs) if cognitive or motor deficits are present.

Prevention

Most cases of kernicterus are preventable with early detection of hyperbilirubinemia.

Universal Newborn Screening

• Obtain transcutaneous bilirubin (TcB) measurements before discharge (usually 24 h for term, 48 h for preterm).
• Apply AAP “hour‑specific” nomograms to decide on phototherapy or discharge.

Breastfeeding Support

• Educate mothers on the importance of early and frequent latch‑on (at least 8‑12 times/day).
• Provide lactation consultant visits within 24 h of birth.

Managing Hemolytic Risk

• Maternal–infant blood typing and Coombs test at delivery.
• If Rh‑negative mother, ensure timely Rh immunoglobulin administration.
• For known G6PD deficiency, avoid oxidative triggers (e.g., certain foods, sulfa drugs).

Medication Vigilance

• Healthcare providers should review drug lists for bilirubin‑displacing agents before prescribing.

Follow‑Up After Discharge

• Schedule a pediatric visit within 48 h for all newborns, earlier if risk factors exist.
• Encourage parents to seek care if the baby appears yellow, sleepy, or is feeding poorly.

Complications

If bilirubin encephalopathy is not promptly treated, the following complications can arise:

• Permanent cerebral palsy (spastic diplegia is most common).
• Severe sensorineural hearing loss, often bilateral.
• Intellectual disability ranging from mild learning difficulties to profound mental retardation.
• Dental enamel hypoplasia (yellow‑brown staining of primary teeth).
• Chronic epilepsy due to cortical scarring.
• Visual disturbances: Nystagmus, strabismus, or optic atrophy.

When to Seek Emergency Care

References

1. Mayo Clinic. “Kernicterus.” https://www.mayoclinic.org. Accessed May 2026.
2. American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant ≥ 35 Weeks’ Gestation.” *Pediatrics*, 2022.
3. World Health Organization. “Neonatal Jaundice: Guidelines for Screening and Management.” WHO Publication, 2021.
4. Cleveland Clinic. “Kernicterus (Bilirubin Encephalopathy).” https://my.clevelandclinic.org. Accessed May 2026.
5. National Institutes of Health, National Institute of Child Health & Human Development. “Bilirubin‑Induced Neurologic Dysfunction.” NIH Fact Sheet, 2023.
6. Shapiro SM, et al. “Long‑term Outcomes of Infants with Severe Hyperbilirubinemia.” *JAMA Pediatrics*, 2020;174(9):e201962.
7. Centers for Disease Control and Prevention. “Neonatal Jaundice.” CDC Health Information for Professionals, 2022.

```